ASIPP WEBINAR-BASED VIRTUAL EDUCATION
Registration Now Open
|
|
We are pleased to announce a series of online webinar review courses to fulfill your board review and credentialing needs. Schedules soon to follow.
Click on the Course below to access registration page.
(Note* This course takes place over two weekends (Friday evening through Sunday) in order to fulfill the necessary topics)
|
|
Multi-jurisdictional Contractor Advisory Committee (CAC) meeting regarding facet joint and medial nerve branch procedure May 28
|
|
Medicare Administrative Contractors (MACs) Will Host a Multi-jurisdictional Contractor Advisory Committee (CAC) Meeting Regarding Facet Joint and Medial Nerve Branch Procedures on May 28th, 2020 from 1-4 pm CST
The purpose of the meeting is to obtain advice from CAC members and subject matter experts (SMEs) regarding the strength of published evidence on Facet Joint and Medial Nerve Branch Procedures. In addition to discussion, the CAC and SME panel will vote on pre-distributed questions. The public is invited to attend as observers.
CAC panels do not make coverage determinations, but MACs benefit from their advice.
The meeting will be hosted by seven Medicare Administrative Contractors. After closely monitoring the COVID-19 pandemic, it was decided to hold the meeting via teleconference/webinar only.
|
|
ASIPP®
Update on COVID-19 News, Resources, and Activity
|
|
While we are still working on an extension of telephone only and telehealth services, we have not yet been provided a confirmation. However, we want to update our members to avoid any confusion. We were under the impression that June 6 was the end of it but we have now learned it is June 30.
CMS MLN Matters
Since many of you have bee open now for a week or so, We hope that things are going well for you. We would like to once again share with you the toolkit we created to assist you in opening up your practice. Since the majority have been open for over a week now, I hope things are going well and everything. Please see the links for the toolkit and other helpful information in the links:
May 4 long letter
;
May 7 short letter
.
Few members have received their payments, but the overwhelming majority have not. While HHS continues to tell us that there is no problem, we are seeing a problem since no one is getting any deposits.
They are saying that it may take 4 weeks from the Wednesday after your application was completed, which is 20 working days rather than what we thought in the past. We will keep you posted as we know more about it.
Click here
for more information on Payment Check Protection Program.
|
|
VIEW ARCHIVED WEBINARS
ASIPP COVID-19 FOR INTERVENTIONAL PAIN PHYSICIANS WEBINAR SERIES – PART 6
ASIPP COVID-19 FOR INTERVENTIONAL PAIN PHYSICIANS WEBINAR SERIES – PART 5
ASIPP COVID-19 FOR INTERVENTIONAL PAIN PHYSICIANS WEBINAR SERIES – PART 4
ASIPP COVID-19 FOR INTERVENTIONAL PAIN PHYSICIANS WEBINAR SERIES – PART 3
Surviving the COVID-19 Epidemic: Protecting Family and Employees and Managing Financial Issues and Burnout – PART 2
Surviving the Coronavirus Pandemic: Practical Advice Every Pain Physician Needs to Know – PART 1
|
|
ABIPP Recognizes Your Knowledge and Expertise
The
American Board of Interventional Pain Physicians
(
ABIPP
)
has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become
ABIPP
certified.
ABIPP
now offers the only competency
certification program for regenerative medicine.
|
|
DATES
ABIPP Part I
- Theoretical written exam - October 3
ABIPP Part II
- Oral and Hands-on practical exam - October 3-4
ABIPP Competency Exam
- includes written, oral, and hands-on practical examinations October 3-4
Combined CSM/CCPM Exam for ABIPP Path
– October 3
Competency Exam in Controlled Substance Management
– October 3
Competency Exam in Coding, Compliance, and Practice Management
- October 3
Regenerative Medicine Competency Exam
- includes written, oral, and hands-on practical examinations – October 3-4
|
|
|
For complete information about the examination requirements and to obtain an application packet, visit
www.abipp.org
or call 270-554-9412 x4217 or by email at
summer@asipp.org
.
|
|
Hospitals and healthcare workers struggle to keep up with the demand as the new coronavirus (COVID-19) spreads across the U.S. and throughout the world.
Hundreds of millions of people are social distancing, quarantining, and sheltering in place to slow down the spread of the virus. The stock market is plunging and the global economy is heading into a recession because of the virus and because of the measures we are enforcing to stop it. Schools are closed. Restaurants, bars, and gyms are closed in many areas of the country. Major sports events, concerts and shows have been cancelled. Perhaps our greatest asset in this fight against the new coronavirus-- healthcare workers-- are becoming infected on the front lines. In the midst of this crisis, Doctor Devi explains what you need to know in a concise and easy-to-understand Question and Answer format.
Dr. Devi Nampiaparampil
, a Harvard-trained doctor and a professor at NYU School of Medicine, breaks down the issues in this clear and compassionate handbook. What makes this virus so dangerous? How can I protect myself and my family? How did this happen?
|
|
What We Know About Coronavirus Tests, Treatment and Vaccines
|
|
How the U.S. is faring in the public-health race to safely reopen schools, businesses and daily life
The U.S. has performed millions of coronavirus tests, but returning the nation to its normal life will require far more.
Some of America’s most prominent public-health doctors say the country must conduct at least six million tests a week to capture most cases and prevent the disease from spreading as the public returns to work and schools. That is about three times the amount the U.S. is doing weekly at this point.
On top of that, the doctors say, the nation needs about 100,000 people to undertake “contact tracing”—getting in touch with those who have had contact with infected people and may now be infected themselves.
|
|
|
|
Pain Physician March/April
2020 Articles
Available Online
|
|
The March/April issue of
Pain Physician
features
Position Statement
Laxmaiah Manchikanti, MD, Christopher J. Centeno, MD, Sairam Atluri, MD, Sheri L. Albers, DO, Shane Shapiro, MD, Gerard A. Malanga, MD, Alaa Abd-Elsayed, MD, MPH, Mairin Jerome, MD, Joshua A. Hirsch, MD, Alan D. Kaye, MD, PhD, Steve M. Aydin, DO, Douglas Beall, MD, Don Buford, MD, Joanne Borg-Stein, MD, Ricardo Buenaventura, MD, Joseph A. Cabaret, MD, Aaron K. Calodney, MD, Kenneth D. Candido, MD, Cameron Cartier, MD, Richard Latchaw, MD, Sudhir Diwan, MD, Ehren Dodson, PhD, Zachary Fausel, MD, Michael Fredericson, MD, Christopher G. Gharibo, MD, Myank Gupta, MD, Adam M. Kaye, PharmD, FASCP, FCPhA, Nebojsa Nick Knezevic, MD, PhD, Radomir Kosanovic, MD, Matthew Lucas, DO, Maanasa V. Manchikanti , R. Amadeus Mason, MD, Kenneth Mautner, MD, Samuel Murala, MD, Annu Navani, MD, Vidyasagar Pampati, MSc, Sarah Pastoriza, DO, Ramarao Pasupuleti, MD, Cyril Philip, MD, Mahendra Sanapati, MD, Theodore Sand, PhD, Rinoo Shah, MD, Amol Soin, MD, Ian Stemper, MS, Bradley W. Wargo, DO, and Philippe Hernigou, MD
Health Policy Review
Laxmaiah Manchikanti, MD, Mahendra R. Sanapati, MD, Amol Soin, MD, Maanasa V. Manchikanti, BS, Vidyasagar Pampati, MSc, Vanila Singh, MD, and Joshua A. Hirsch, MD
Systematic Reviews
Jianwei Wang, MS, Zifeng Xu, MD, Zhou Feng, MS, Rui Ma, BS, and Xiaoyu Zhang, MS
Felipe Araya-Quintanilla, MSc, Hector Gutierrez-Espinoza, PhD, Maria Jesus Munoz-Yanez, MSc, Ursula Sanchez-Montoya, MSc, and Juan Lopez-Jeldes, MSc
|
|
What Is Known About the Rare Coronavirus-Related Illness in Children
|
|
Kids hospitalized with the mysterious syndrome mostly test positive for the coronavirus or its antibodies, leading researchers to believe the two are connected
THE NUMBER OF CHILDREN with a new and rare illness linked to the coronavirus is growing while researchers try to find out more about the condition.
As of Tuesday, the illness has popped up in almost half of U.S. states, including New York, New Jersey, Connecticut, Louisiana, California and Kentucky. It's also been reported in some European countries.
New York health officials are following about 150 possible cases of the syndrome. Three children in the state have died from it. In New Jersey, health officials are aware of at least a dozen cases.
Kids hospitalized with the syndrome mostly test positive for the coronavirus or its antibodies, leading researchers to believe the two are connected.
|
|
COVID-19 Sequelae Can Linger for Weeks
|
|
— Even patients with mild cases describe persistent fatigue, trouble breathing, cardiac issues
When he developed a low fever at the end of March, Jarett DeSanti did not think it was related to COVID-19. But as his fever persisted, his body weakened, and cases continued to emerge in New York, DeSanti's doctor insisted he get tested.
DeSanti, a 35-year-old security officer from Brentwood, New York, tested positive for COVID-19 on March 27, and his moderate illness, doctors said, could be managed at home.
In the following days, his fever worsened, climbing to 102 °F. He had nausea and other gastrointestinal symptoms. On day 10, he got a chest x-ray confirming pneumonia. He lost his sense of smell, and couldn't sleep.
When the fever broke on day 13, his body started to recover. DeSanti tested positive for antibodies, and planned to donate plasma at his local hospital.
But 47 days after first testing positive for COVID-19, his symptoms have yet to completely subside. He still suffers weakness, a daily low-grade fever, shortness of breath, increased heart rate, and the constant anxiety that his illness will worsen yet again.
|
|
Lawsuits in the Time of COVID-19: An Overview
|
|
The coronavirus disease 2019 (COVID-19) pandemic currently sweeping across the United States is a public health emergency that has had an unprecedented effect on healthcare workers. Retired physicians, students in their last year of medical school, and practitioners in other areas have all been called upon to help the overburdened healthcare system, and they have jumped in despite risks to themselves.
But are health practitioners putting themselves at risk, legally, by stepping up?
When this situation ends, there are likely to be 4 types of lawsuits that will arise.
Lawsuits Related to COVID-19 Treatment
Healthcare practitioners are being forced to function in almost battlefield situations in some states. Critical and difficult decisions about who gets ventilators, who gets trial medications, and similar choices need to be made at the spur of the moment. It’s a terrible and difficult way to have to practice medicine.
|
|
We are currently looking for reviewers for Pain Physician
We would like to take this opportunity to ask if you would be interested in a position as a Reviewer on the Editorial Board for Pain Physician or if you have a recommendation for someone who might be interested.
Editorial Board responsibilities are as follows:
- Review a minimum of 6 manuscripts per year.
- Failure to review 2 manuscripts consecutively or 60% of the manuscripts sent will disqualify one from Editorial Board Membership.
|
|
For more information or to submit your letter of interest, please e-mail:
|
|
ASIPP
®
Partners with Fedora Billing And Revenue Cycle
Management Company
|
|
After long discussions, in addition to our NorCal liability program for
ASIPP
®
members, now we are able to offer unique benefits for revenue cycle management with billing, etc.
Fedora
is a company known to many of our board members and others.
ASIPP
®
has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis.
Some of the
ASIPP
®
Billing Program highlights are below:
Up to 50% savings for
ASIPP
®
members for their billing or revenue cycle management for their offices and surgery centers:
- Expertise in interventional pain management billing for all types of services
- 99% Clearing House Rate
- 95% First-Time Claim Passage
- 23.4 Average Days in A/R
- Eligibility and Benefits Verification
- Pre-Certification/Prior Authorization
- Denials and A/R Management
|
|
Join The Group Purchasing Organization Today
|
|
ASIPP
®
has formed a partnership with
Henry Schein
and
PedsPal
, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.
It will be easy for
ASIPP
®
members in good standing to enroll today and begin to realize the savings this partnership can bring. Members can join or see sample prices by going to
http://pedspal.org/asipp/default.html
Click on “view our discounted supplier prices” (Username:ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!
|
|
NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated
|
|
A treatment regimen that includes the investigational antiviral remdesivir plus the Janus kinase inhibitor baricitinib is being evaluated in hospitalized adults with coronavirus disease 2019 (COVID) in a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The ACTT 2 study, which is expected to enroll over 1000 patients across approximately 100 US and international sites, is assessing the combination therapy vs remdesivir monotherapy in patients with confirmed SARS-CoV-2 infection who have either a need for supplemental oxygen, abnormal chest X-ray, or illness requiring mechanical ventilation.
Patients will be randomized to receive oral baricitinib (for up to 14 days of treatment) plus intravenous (IV) remdesivir (for up to 10 days of treatment) or placebo plus IV remdesivir; if necessary, baricitinib will be crushed and given through a nasogastric tube.
The primary end point of the study is time to recovery, defined as a patient no longer requiring supplemental oxygen or ongoing medical care in the hospital; patient outcomes at day 15 will also be evaluated as a key secondary outcome measure using an ordinal 8-point scale ranging from fully recovered to death.
|
|
FDA Greenlights Study to Evaluate Opaganib in Patients With Moderate to Severe COVID-19
|
|
The Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Opaganib is an investigational, first-in-class, oral, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-inflammatory and antiviral properties. Preclinical data have shown the potential of opaganib to inhibit viral replication and reduce levels of pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha, which have been found to be elevated in patients with coronavirus disease 2019 (COVID-19).
The double-blind, placebo-controlled phase 2a study will enroll up to 40 patients with moderate to severe COVID-19 and pneumonia who require hospitalization and supplemental oxygenation. Patients will be randomized to receive either opaganib or placebo in addition to standard of care. The primary end point is the reduction in total oxygen requirements over the course of the 14 day treatment period. Secondary end points include time to 50% reduction in oxygen requirements, as well as the proportion of patients without fever and with negative nasal swabs, both at day 14.
|
|
Essentials of Regenerative Medicine in Interventional
Pain Management
|
|
|
|
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.
Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
|
|
|
ORDER
|
Essentials of Regenerative Medicine in IPM
|
|
Control Your Waiting Room TV
Customized waiting room TV exclusively for
ASIPP
®
members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
|
|
|
|
|
OH
/
KY
ANNUAL MEETING 2020
SOCIETIES OF INTERVENTIIONAL PAIN PHYSICIAN
AUGUST 21-23 | WESTIN CINCINNATI
|
|
|
|
|
GSIPP 16th Annual Pain Summit
|
|
The Ritz-Carlton Reynolds Plantation
Lake Oconee
|
|
|
|
|
|
|
FSIPP/FSPM
Annual Meeting
|
|
|
|
|
|
|
|
2020 12th Annual Scientific
Meeting
|
|
|
|
|
|
|
|
|
|
